Abstract Background Risankizumab, an inhibitor of the p19 subunit of IL-23, received its UK approval for use in ulcerative colitis (UC) in August 2024. We report the outcomes of patients with UC treated with Risankizumab at a single centre in the North West of England. Methods Patients who had been commenced on Risankizumab for UC were identified. Baseline demographics were obtained (Table 1). Exclusion criteria included patients who had not completed the 3 loading doses of Risankizumab and any patient who had not had a simple colitis clinical activity index (SCCAI); a faecal calprotectin (FC) or Ulcerative colitis endoscopic index of severity (UCEIS) score either at baseline or within the study period. Results Seventeen patients were commenced on Risankizumab at our centre. Three were excluded as they had not yet completed the loading regime. Two patients were excluded as they had not undergone assessment with UCEIS, FC or SCCAI. Twelve patients were therefore included. All patients had a baseline FC and UCEIS, 7 had a recorded baseline SCCAI. Four of the patients with a baseline SCCAI had a further assessment at 3-6 months. Three had an improvement at 3 months (average 5.3 reduced to 1) and the other patient worsened (increased from 4 to 8 at 6 months). Seven patients underwent endoscopic evaluation within 6 months. The UCEIS improved with each patient with the average UCEIS score reducing from 4.86 to 2.86. 4 patients had a stable or worsening trend of FC with 6 improving (average improvement 35%). Median FC was 264 µg/g at baseline and 112 µg/g at 3-6 months follow up. The mean FC trend is shown in figure 1. No adverse reactions to Risankizumab were identified. The only hospitalisations identified were in the same patient and not related to Risankizumab (pain following a colonoscopy and back pain following a lumbar puncture). Conclusion Within this small real-world cohort, Risankizumab appears to be safe and effective as a treatment in achieving clinical and endoscopic response in patients with UC. Further real world studies are required to assess longer term outcomes. Conflict of interest: Dr. Morgan, James: Consultancy fees from Takeda and Amgen. Speaker fees from Abbvie and Dr Falk. Travel grants from Tillotts, Johnson & Johnson and Alfasigma. Jafar, Wisam: sponsorship/speaker fees Abbvie Lilly Ferring Pharmacosmos Johnson and Johnson Miller, Bethany: Travel grant from Lilly White, Katherine: Travel grant from Tillotts Table 1: Baseline demographics
Morgan et al. (Thu,) studied this question.